https://ir.fibrobiologics.com/ https://ir.fibrobiologics.com/news-events/press-releases https://ir.fibrobiologics.com/news-events/ir-calendar https://ir.fibrobiologics.com/news-events/presentations https://ir.fibrobiologics.com/news-events/email-alerts https://ir.fibrobiologics.com/company-information/contacts https://ir.fibrobiologics.com/company-information/faq https://ir.fibrobiologics.com/financial-information/financial-results https://ir.fibrobiologics.com/stock-data/quote-chart https://ir.fibrobiologics.com/stock-data/historical-data https://ir.fibrobiologics.com/stock-data/analyst-coverage https://ir.fibrobiologics.com/sec-filings/all-sec-filings https://ir.fibrobiologics.com/sec-filings/annual-reports https://ir.fibrobiologics.com/sec-filings/quarterly-reports https://ir.fibrobiologics.com/sec-filings/section-16-filings https://ir.fibrobiologics.com/corporate-governance https://ir.fibrobiologics.com/corporate-governance/board-committees https://ir.fibrobiologics.com/corporate-governance/governance-documents https://ir.fibrobiologics.com/news-events/press-releases/detail/110/fibrobiologics-announces-closing-of-3-million-public-offering https://ir.fibrobiologics.com/news-events/press-releases/detail/109/fibrobiologics-announces-pricing-of-3-million-public-offering https://ir.fibrobiologics.com/news-events/press-releases/detail/108/fibrobiologics-announces-successful-manufacturing-of-cywc628-drug-product-to-support-upcoming-diabetic-foot-ulcer-clinical-trial https://ir.fibrobiologics.com/news-events/press-releases/detail/107/fibrobiologics-announces-reverse-stock-split-to-regain-compliance-with-nasdaqs-bid-price-requirement https://ir.fibrobiologics.com/news-events/press-releases/detail/106/fibrobiologics-announces-advances-in-burn-treatment-using-proprietary-fibroblast-spheroid-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/105/fibrobiologics-completes-site-onboarding-for-phase-12-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers https://ir.fibrobiologics.com/news-events/press-releases/detail/104/fibrobiologics-inc-announces-issuance-of-u-s-patent-covering-fibroblast-cell-therapy-for-the-treatment-of-osteoporosis https://ir.fibrobiologics.com/news-events/press-releases/detail/103/fibrobiologics-to-present-at-the-bio-investment-growth-summit https://ir.fibrobiologics.com/news-events/press-releases/detail/102/fibrobiologicsreportsfull-year-2025-financial-resultsand-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/101/fibrobiologics-granted-extension-by-nasdaq-to-regain-compliance https://ir.fibrobiologics.com/news-events/press-releases/detail/100/fibrobiologics-chairman-ceo-pete-oheeron-selected-to-present-at-a4lis-h-span-summit-at-georgetown-university https://ir.fibrobiologics.com/news-events/press-releases/detail/99/fibrobiologics-announces-issuance-of-canadian-patent-covering-novel-fibroblast-based-treatment-for-cachexia https://ir.fibrobiologics.com/news-events/press-releases/detail/98/fibrobiologics-to-present-at-the-dealflow-discovery-conference https://ir.fibrobiologics.com/news-events/press-releases/detail/97/fibrobiologics-ceo-issues-letter-to-shareholders https://ir.fibrobiologics.com/news-events/press-releases/detail/96/fibrobiologics-to-present-at-9th-annual-bfc-global-healthcare-business-development-and-investment-conference https://ir.fibrobiologics.com/news-events/press-releases/detail/95/fibrobiologics-announces-positive-preclinical-results-for-a-fibroblast-spheroid-derived-chondrocyte-fsdc-spheroid-therapy-for-degenerative-disc-disease https://ir.fibrobiologics.com/news-events/press-releases/detail/94/fibrobiologics-files-ind-application-with-the-u-s-fda-to-advance-clinical-development-of-cyps317-in-patients-with-psoriasis https://ir.fibrobiologics.com/news-events/press-releases/detail/93/fibrobiologics-announces-closing-of-1-7-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.fibrobiologics.com/news-events/press-releases/detail/92/fibrobiologics-announces-1-7-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.fibrobiologics.com/news-events/press-releases/detail/91/fibrobiologics-files-patent-application-covering-novel-fibroblast-based-chondrocyte-spheroid-platform-for-orthopedic-and-musculoskeletal-conditions https://ir.fibrobiologics.com/news-events/press-releases/detail/90/fibrobiologics-announces-payoff-of-outstanding-debt https://ir.fibrobiologics.com/news-events/press-releases/detail/89/fibrobiologics-announces-closing-of-1-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.fibrobiologics.com/news-events/press-releases/detail/88/fibrobiologics-announces-1-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.fibrobiologics.com/news-events/press-releases/detail/87/fibrobiologics-receives-hrec-approval-for-phase-12-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers https://ir.fibrobiologics.com/news-events/press-releases/detail/86/fibrobiologics-announces-closing-of-4-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.fibrobiologics.com/news-events/press-releases/detail/85/fibrobiologics-announces-pricing-of-4-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.fibrobiologics.com/news-events/press-releases/detail/84/fibrobiologics-reports-third-quarter-2025-financial-results-and-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/83/fibrobiologics-to-present-at-bio-europe-2025 https://ir.fibrobiologics.com/news-events/press-releases/detail/82/fibrobiologics-to-present-at-the-2025-thinkequity-conference https://ir.fibrobiologics.com/news-events/press-releases/detail/81/fibrobiologics-to-present-at-2025-cell-gene-meeting-on-the-mesa https://ir.fibrobiologics.com/news-events/press-releases/detail/80/fibrobiologics-leadership-authors-opinion-editorial-highlighting-fibroblast-cells-therapeutic-advantages-over-traditional-stem-cell-therapies https://ir.fibrobiologics.com/news-events/press-releases/detail/79/fibrobiologics-announces-positive-ind-enabling-updates-demonstrating-potential-of-fibroblast-spheroids-in-chronic-relapse-psoriasis-treatment https://ir.fibrobiologics.com/news-events/press-releases/detail/78/fibrobiologics-announces-significant-advancements-in-bone-marrow-organoid-platform-enabling-development-for-cancer-and-immune-related-therapies https://ir.fibrobiologics.com/news-events/press-releases/detail/77/fibrobiologics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference https://ir.fibrobiologics.com/news-events/press-releases/detail/76/fibrobiologics-reports-second-quarter-2025-financial-results-and-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/75/fibrobiologics-files-patent-for-methods-of-generating-multipotent-cells-from-donor-tissue-for-clinical-applications https://ir.fibrobiologics.com/news-events/press-releases/detail/74/fibrobiologics-to-present-at-the-advanced-wound-care-summit-usa https://ir.fibrobiologics.com/news-events/press-releases/detail/73/fibrobiologics-confirms-ability-to-manufacture-cybrocell-for-degenerative-disc-disease-and-cartilage-repair-programs-from-existing-cywc628-master-cell-bank https://ir.fibrobiologics.com/news-events/press-releases/detail/72/fibrobiologics-to-present-at-exclusive-live-investor-webinar-and-qa-session-on-july-10 https://ir.fibrobiologics.com/news-events/press-releases/detail/71/fibrobiologics-closes-third-5-million-tranche-of-25-million-financing https://ir.fibrobiologics.com/news-events/press-releases/detail/70/fibrobiologics-to-present-at-the-bio-international-convention-2025 https://ir.fibrobiologics.com/news-events/press-releases/detail/69/fibrobiologics-appoints-jason-d-davis-cpa-as-chief-financial-officer https://ir.fibrobiologics.com/news-events/press-releases/detail/68/fibrobiologics-presents-at-the-society-for-investigative-dermatology-annual-meeting https://ir.fibrobiologics.com/news-events/press-releases/detail/67/fibrobiologics-reports-first-quarter-2025-financial-results-and-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/66/fibrobiologics-presents-at-the-thymus-2025-meeting https://ir.fibrobiologics.com/news-events/press-releases/detail/65/fibrobiologics-to-present-at-the-cell-gene-meeting-on-the-mediterranean https://ir.fibrobiologics.com/news-events/press-releases/detail/64/fibrobiologics-unveils-new-and-expanded-houston-laboratory-space-to-pursue-innovation-and-breakthroughs-in-fibroblast-based-therapeutics https://ir.fibrobiologics.com/news-events/press-releases/detail/63/fibrobiologics-announces-scientific-advancement-in-confirmation-results-of-brain-tissue-repair https://ir.fibrobiologics.com/news-events/press-releases/detail/62/fibrobiologics-reports-full-year-2024-financial-results-and-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/61/fibrobiologics-announces-2025-annual-meeting-of-stockholders https://ir.fibrobiologics.com/news-events/press-releases/detail/60/fibrobiologics-to-present-at-the-german-nordic-joint-extracellular-matrix-meeting https://ir.fibrobiologics.com/news-events/press-releases/detail/59/fibrobiologics-files-patent-for-novel-approach-to-modulate-mitochondrial-activity-using-fibroblast-based-therapeutics https://ir.fibrobiologics.com/news-events/press-releases/detail/58/fibrobiologics-and-charles-river-announce-completion-and-release-of-cywc628-master-cell-bank-for-the-manufacturing-of-fibroblast-cell-based-wound-healing-therapeutic https://ir.fibrobiologics.com/news-events/press-releases/detail/57/fibrobiologics-to-host-in-person-analyst-day-to-provide-research-development-updates https://ir.fibrobiologics.com/news-events/press-releases/detail/56/fibrobiologics-closes-second-5-million-tranche-of-25-million-financing https://ir.fibrobiologics.com/news-events/press-releases/detail/55/fibrobiologics-announces-25-million-financing https://ir.fibrobiologics.com/news-events/press-releases/detail/54/fibrobiologics-files-patent-application-for-a-cell-based-therapeutic-for-the-treatment-of-splenomegaly https://ir.fibrobiologics.com/news-events/press-releases/detail/53/fibrobiologics-files-patent-application-covering-reduction-of-blood-clots-associated-with-instant-blood-mediated-inflammatory-reaction-ibmir-in-cell-based-therapeutics https://ir.fibrobiologics.com/news-events/press-releases/detail/52/fibrobiologics-reports-third-quarter-2024-financial-results-and-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/51/fibrobiologics-announces-updates-for-novel-artificial-thymus-organoid-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/50/fibrobiologics-to-present-at-the-2024-thinkequity-conference-and-bio-europe-2024 https://ir.fibrobiologics.com/news-events/press-releases/detail/49/fibrobiologics-and-charles-river-announce-collaboration-to-manufacture-fibroblast-cell-based-therapies-for-chronic-diseases https://ir.fibrobiologics.com/news-events/press-releases/detail/48/fibrobiologics-issued-patent-for-fibroblast-delivery-of-tumor-inhibitory-agents-by-the-european-patent-office https://ir.fibrobiologics.com/news-events/press-releases/detail/47/fibrobiologics-to-participate-in-a-fireside-chat-at-2024-maxim-healthcare-virtual-summit https://ir.fibrobiologics.com/news-events/press-releases/detail/46/fibrobiologics-to-present-at-2024-cell-gene-meeting-on-the-mesa https://ir.fibrobiologics.com/news-events/press-releases/detail/45/fibrobiologics-engages-southern-star-research-as-cro-in-australia https://ir.fibrobiologics.com/news-events/press-releases/detail/44/fibrobiologics-announces-filing-of-patent-application-for-generation-of-three-dimensional-organoids-using-fibroblast-cell-based-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/43/fibrobiologics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference https://ir.fibrobiologics.com/news-events/press-releases/detail/42/fibrobiologics-announces-filing-of-patent-application-for-wound-healing-using-an-adhesive-bandage-with-fibroblast-cell-based-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/41/fibrobiologics-files-2024-second-quarter-report https://ir.fibrobiologics.com/news-events/press-releases/detail/40/fibrobiologics-to-present-at-jonestrading-healthcare-summit-2024 https://ir.fibrobiologics.com/news-events/press-releases/detail/39/fibrobiologics-announces-preliminary-proof-of-concept-for-novel-artificial-thymus-organoid-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/38/fibrobiologics-set-to-join-russell-2000-index https://ir.fibrobiologics.com/news-events/press-releases/detail/37/fibrobiologics-to-present-at-extracellular-matrix-pharmacology-congress-2024 https://ir.fibrobiologics.com/news-events/press-releases/detail/36/fibrobiologics-announces-2024-annual-meeting-of-stockholders https://ir.fibrobiologics.com/news-events/press-releases/detail/35/fibrobiologics-files-2024-first-quarter-report https://ir.fibrobiologics.com/news-events/press-releases/detail/34/fibrobiologics-to-present-at-the-bio-international-convention-2024 https://ir.fibrobiologics.com/news-events/press-releases/detail/33/fibrobiologics-plans-to-collaborate-with-charles-river-to-manufacture-fibroblast-based-spheroids https://ir.fibrobiologics.com/news-events/press-releases/detail/32/fibrobiologics-granted-patent-for-regeneration-of-cartilage-type-cells-by-the-australian-patent-office https://ir.fibrobiologics.com/news-events/press-releases/detail/31/fibrobiologics-presents-data-from-dermal-fibroblast-spheroid-based-treatment-of-chronic-wounds-in-a-diabetes-mouse-model-at-advanced-wound-care-summit-usa https://ir.fibrobiologics.com/news-events/press-releases/detail/30/fibrobiologics-files-patent-application-covering-fibroblast-based-technology-for-the-potential-treatment-of-lupus https://ir.fibrobiologics.com/news-events/press-releases/detail/29/fibrobiologics-announces-preliminary-proof-of-concept-for-fibroblast-based-diabetes-treatment https://ir.fibrobiologics.com/news-events/press-releases/detail/28/fibrobiologics-to-present-at-advanced-wound-care-summit-usa https://ir.fibrobiologics.com/news-events/press-releases/detail/27/fibrobiologics-appoints-ruben-a-garcia-as-general-counsel https://ir.fibrobiologics.com/news-events/press-releases/detail/26/fibrobiologics-files-2023-form-10-k-annual-report https://ir.fibrobiologics.com/news-events/press-releases/detail/25/fibrobiologics-to-present-preclinical-and-clinical-data-at-the-2024-americas-committee-for-treatment-and-research-in-multiple-sclerosis-actrims-forum https://ir.fibrobiologics.com/news-events/press-releases/detail/24/fibrobiologics-presents-preclinical-data-at-the-2024-keystone-symposia-for-systemic-autoimmune-and-autoinflammatory-diseases https://ir.fibrobiologics.com/news-events/press-releases/detail/23/fibrobiologics-announces-three-united-states-patents-for-fibroblast-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/22/fibrobiologics-announces-three-japanese-patents-on-fibroblast-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/21/fibrobiologics-announces-direct-listing-on-nasdaq-under-the-stock-ticker-fblg https://ir.fibrobiologics.com/news-events/press-releases/detail/20/fibrobiologics-announces-anticipated-listing-day https://ir.fibrobiologics.com/news-events/press-releases/detail/19/fibrobiologics-to-present-at-biotech-showcase-2024 https://ir.fibrobiologics.com/news-events/press-releases/detail/18/fibrobiologics-to-host-investor-day https://ir.fibrobiologics.com/news-events/press-releases/detail/5/fibrobiologics-to-provide-company-update-at-upcoming-conferences https://ir.fibrobiologics.com/news-events/press-releases/detail/6/fibrobiologics-dedicates-laboratory-facility-as-the-newlin-linscomb-lab-for-cell-therapeutics https://ir.fibrobiologics.com/news-events/press-releases/detail/7/fibrobiologics-to-present-corporate-update-at-2023-bio-international-convention https://ir.fibrobiologics.com/news-events/press-releases/detail/8/fibrobiologics-sets-another-record-as-highest-amount-raised-per-biotech-investor-in-startengine-com-history https://ir.fibrobiologics.com/news-events/press-releases/detail/9/fibrobiologics-sets-record-as-fastest-rising-biotech-in-history-with-startengine-com https://ir.fibrobiologics.com/news-events/press-releases/detail/10/fibrobiologics-launches-public-funding-campaign-with-startengine-com https://ir.fibrobiologics.com/news-events/press-releases/detail/11/fibrobiologics-appoints-mark-c-andersen-as-chief-financial-officer https://ir.fibrobiologics.com/news-events/press-releases/detail/12/fibrobiologics-presents-preclinical-data-at-the-2022-consortium-of-multiple-sclerosis-centers-annual-meeting https://ir.fibrobiologics.com/news-events/press-releases/detail/13/fibrobiologics-adds-microbiologist-kathleen-kate-rubins-ph-d-to-scientific-advisory-board https://ir.fibrobiologics.com/news-events/press-releases/detail/14/fibrobiologics-introduces-scientific-advisory-board https://ir.fibrobiologics.com/news-events/press-releases/detail/15/fibrobiologics-secures-100-million-capital-commitment-from-gem-as-company-seeks-to-go-public https://ir.fibrobiologics.com/news-events/press-releases/detail/16/fibrobiologics-appoints-hamid-khoja-ph-d-as-chief-scientific-officer https://ir.fibrobiologics.com/news-events/press-releases/detail/17/fibrobiologics-announces-inaugural-board-of-directors https://ir.fibrobiologics.com/privacy-policy https://ir.fibrobiologics.com/disclaimer https://ir.fibrobiologics.com/sitemap https://ir.fibrobiologics.com/accessibility-statement